Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Hedwig Sutterlüty
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
        • Research Projects
        • Group Members
        • Former Group Members
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

 

Hedwig Sutterlüty, Assoc. Prof. Priv.-Doz. Mag.
Gruppenleiterin
E-Mail: hedwig.sutterluety [at] meduniwien [dot] ac [dot] at
Phone.: +43 (0)1 40160 - 57526
Fax: +43 (0)1 40160 - 957500

Research Focus

We are interested in three major topics:

  1. Molecular analysis of signal transduction pathways involved in regulation of normal and tumour cells;
  2. Characterisation of mechanisms involved in intracellular regulation of cell proliferation;
  3. Investigations analyzing the role of micro RNAs as important modulator of gene expression in cancer.

 
Group Members

Videos

Selected Publications

MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.
Vanas V, Haigl B, Stockhammer V, Sutterluty-Fall H.
PLoS One. 2016 Aug 11;11(8):e0161023. doi: 10.1371/journal.pone.0161023. eCollection 2016.

Differential Effects of Variations at Codon 106 on Sprouty2 Functions in Lung Cancer-Derived Cells.
Kral R, Doriguzzi A, Mayer CE, Krenbek D, Setinek U, Sutterluty-Fall H.
J Cell Biochem. 2016 Aug;117(8):1822-32. doi: 10.1002/jcb.25482. Epub 2016 Jan 21.

The increased Sprouty4 expression in response to serum is transcriptionally
controlled by Specific protein 1

Doriguzzi A, Haigl B, Gsur A, Sutterlüty-Fall H.
Int J Biochem Cell Biol. 2015 Jul;64:220-8. doi: 10.1016/j.biocel.2015.04.017. Epub 2015 May 6.

Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation.
Haigl B, Vanas V, Setinek U, Hegedus B, Gsur A, Sutterluty-Fall H.
Int J Oncol. 2014 Apr;44(4):1325-34. doi: 10.3892/ijo.2014.2272. Epub 2014 Jan 22.

Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells.
Rathmanner N, Haigl B, Vanas V, Doriguzzi A, Gsur A, Sutterluty-Fall H.
FEBS Lett. 2013 Aug 19;587(16):2597-605. doi: 10.1016/j.febslet.2013.06.040. Epub 2013 Jul 4.

 

 

All Publications:

PubmedDatabase (Sutterluty)
PubmedDatabase (Sutterluty-Fall)

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt